Clinical Observation On The Efficacy Of Tongxinluo Capsule In The Treatment Of Stable Angina Pectoris (Qi Deficiency And Blood Stasis Type) After PCI Of Coronary Heart Diseas

Purpose: To examine the clinical efficacy of Tongxinluo capsule in the treatment of stable angina pectoris(Qi deficiency and blood stasis type)after PCI for coronary artery disease,and to provide a new clinical basis for the treatment of patients with angina pectoris attacks after PCI with traditional Chinese medicine.Material and method: Sixty patients with stable angina pectoris after PCI for coronary artery disease diagnosed in the outpatient clinic or ward of the Department of Stem Clinic/Geriatrics of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine from August 2021 to July 2022 and meeting the Chinese medical evidence of Qi deficiency and blood stasis type were included.The 60 patients were randomly divided into two groups,in which the control group(n=30)was given the conventional Western medical treatment regimen;the treatment regimen of the experimental group(n=30)was combined with Tongxinluo capsule on top of the regimen applied in the control group.The duration of the regimen in both groups was 35 days.The angina pectoris symptom scores and efficacy,Seattle angina pectoris,TCM evidence scores and efficacy,and safety indexes were observed and analyzed before and after the intervention of patients in the control and experimental groups with different treatment regimens.The relevant data obtained above were analyzed by statistical software SPSS(version 26.0).Result:1.Angina symptom score and its efficacy: the angina score of both groups decreased after the intervention of different treatment plans compared with that before the intervention(P < 0.01),and the degree of attack was also reduced after the intervention.The total effective rate of the test group was 90%,and the total effective rate of the control group was 80%,and the efficacy of the test group was significantly better than that of the control group(P < 0.05).2.Chinese medicine evidence points and their efficacy: after the intervention of different treatment plans,the Chinese medicine evidence points of patients in both groups were lower than those before the intervention(P < 0.01),and the Chinese medicine symptoms of patients in both groups were improved after the intervention.The total effective rate of the test group was 93%,and the total effective rate of the control group was 83%,and the efficacy of the test group was significantly better than that of the control group(P < 0.05).3.Seattle angina score: The Seattle scale was used to score the two groups of patients before and after the intervention in five different dimensions,and the Seattle angina score in both groups increased after the intervention with different protocols compared with that before the intervention(P < 0.01).And except for PL,the efficacy of the remaining four dimensions was significantly better in the test group than in the control group(P < 0.05).4.Safety indexes: In this clinical efficacy observation,no drug-related adverse events were found in the two groups of patients treated with different protocols,and no abnormalities in the relevant safety indexes were detected,so the intervention protocols used in both groups were safe.Conclusion:1.The combined intervention of Tongxinluo capsule and conventional western medicine can significantly reduce the anginal symptoms and TCM syndrome score,reduce the degree of attack,improve the TCM syndrome,improve the Seattle angina score,and improve the quality of life of patients with stable angina after PCI for qi deficiency and blood stasis type of coronary artery disease.2.The combination of Tongxinluo capsule and conventional western medicine in the treatment of stable angina pectoris(Qi deficiency and blood stasis type)after PCI for coronary heart disease has both significant therapeutic effects and better safety profile,providing a better treatment option for patients with angina pectoris attacks after PCI.